Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 2 , Pages 147-157 , April 2009

Pathogenesis of primary adrenal insufficiency

References 

  1. Addison T. On the constitutional and local effects of disease of the suprarenal capsules. In: A collection of the published writings of the late Thomas Addison MD, Physician to Guy's Hospital. New Sydenham Society (1868) London Reprinted in Medical Classics 19392: 244–293.
  2. Betterle C, Dal Pra C, Mantero F, et al. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocrine Reviews. 2002;23:327–364
  3. Myhre AG, Undlien DE, Løvås K, et al. Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. The Journal of Clinical Endocrinology and Metabolism. 2002;87:618–623
  4. Mason AS, Meade TW, Lee JA, et al. Epidemiological and clinical picture of Addison's disease. Lancet. 1968;2:744–747
  5. Bergthorsdottir R, Leonsson-Zachrisson M, Oden A, et al. Premature mortality in patients with Addison's disease: a population-based study. The Journal of Clinical Endocrinology and Metabolism. 2006;91:4849–4853
  6. Arlt W, Allolio B. Adrenal insufficiency. Lancet. 2003;361:1881–1893
  7. Coco G, Dal Pra C, Presotto F, et al. Estimated risk for developing autoimmune Addison's disease in patients with adrenal cortex autoantibodies. The Journal of Clinical Endocrinology and Metabolism. 2006;91:1637–1645
  8. Winqvist O, Karlsson FA, Kämpe O. 21-Hydroxylase, a major autoantigen in idiopathic Addison's disease. Lancet. 1992;339:1559–1562
  9. Falorni A, Nikoshkov A, Laureti S, et al. High diagnostic accuracy for idiopathic Addison's disease with a sensitive radiobinding assay for autoantibodies against recombinant human 21-hydroxylase. The Journal of Clinical Endocrinology and Metabolism. 1995;80:2752–2755
  10. Ten S, New M, Maclaren N. Clinical review 130: Addison's disease 2001. The Journal of Clinical Endocrinology and Metabolism. 2001;86:2909–2922
  11. Bakaeen FG, Walkes JC, Reardon MJ. Heparin-induced thrombocytopenia associated with bilateral adrenal hemorrhage after coronary artery bypass surgery. The Annals of Thoracic Surgery. 2005;79:1388–1390
  12. Presotto F, Fornasini F, Betterle C, et al. Acute adrenal failure as the heralding symptom of primary antiphospholipid syndrome: report of a case and review of the literature. European Journal of Endocrinology. 2005;153:507–514
  13. Andersson HC, Frentz J, Martinez JE, et al. Adrenal insufficiency in Smith-Lemli-Opitz syndrome. American Journal of Medical Genetics. 1999;82:382–384
  14. Handschug K, Sperling S, Yoon SJ, et al. Triple A syndrome is caused by mutations in AAAS, a new WD-repeat protein gene. Human Molecular Genetics. 2001;10:283–290
  15. Sanaker PS, Husebye ES, Fondenes O, et al. Clinical evolution of Kearns-Sayre syndrome with polyendocrinopathy and respiratory failure. Acta neurologica Scandinavica. Supplementum. 2007;187:64–67
  16. Walker AP, Muscatelli F, Stafford AN, et al. Mutations and phenotype in isolated glycerol kinase deficiency. American Journal of Human Genetics. 1996;58:1205–1211
  17. Bergrem H, Refvem OK. Altered prednisolone pharmacokinetics in patients treated with rifampicin. Acta Medica Scandinavica. 1983;213:339–343
  18. Løvås K, Husebye ES. High prevalence and increasing incidence of Addison's disease in western Norway. Clinical Endocrinology. 2002;56:787–791
  19. Laureti S, Vecchi L, Santeusanio F, et al. Is the prevalence of Addison's disease underestimated?. The Journal of Clinical Endocrinology and Metabolism. 1999;84:1762
  20. Willis AC, Vince FP. The prevalence of Addison's disease in Coventry, UK. Postgraduate Medical Journal. 1997;73:286–288
  21. Nerup J. Addison's disease–clinical studies. A report fo 108 cases. Acta Endocrinologica. 1974;76:127–141
  22. Harjutsalo V, Sjoberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet. 2008;371:1777–1782
  23. Falorni A, Laureti S, De Bellis A, et al. Italian addison network study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. The Journal of Clinical Endocrinology and Metabolism. 2004;89:1598–1604
  24. Myhre AG, Aarsetøy H, Undlien DE, et al. High frequency of coeliac disease among patients with autoimmune adrenocortical failure. Scandinavian Journal of Gastroenterology. 2003;38:511–515
  25. Skinningsrud B, Husebye ES, Pearce SH, et al. Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency. The Journal of Clinical Endocrinology and Metabolism. 2008;93:3310–3317
  26. Neufeld M, Maclaren NK, Blizzard RM. Two types of autoimmune Addison's disease associated witsh different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore). 1981;60:355–362
  27. Anderson JR, Goudie RB, Gray KG, et al. Auto-antibodies in Addison's disease. Lancet. 1957;272:1123–1124
  28. Chen S, Sawicka J, Betterle C, et al. Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure. The Journal of Clinical Endocrinology and Metabolism. 1996;81:1871–1876
  29. Falorni A, Laureti S, Nikoshkov A, et al. 21-hydroxylase autoantibodies in adult patients with endocrine autoimmune diseases are highly specific for Addison's disease. Belgian Diabetes Registry Clinical and Experimental Immunology. 1997;107:341–346
  30. Laureti S, Aubourg P, Calcinaro F, et al. Etiological diagnosis of primary adrenal insufficiency using an original flowchart of immune and biochemical markers. The Journal of Clinical Endocrinology and Metabolism. 1998;83:3163–3168
  31. Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. The Journal of Clinical Endocrinology and Metabolism. 2006;91:2843–2850
  32. De Bellis AA, Falorni A, Laureti S, et al. Time course of 21-hydroxylase antibodies and long-term remission of subclinical autoimmune adrenalitis after corticosteroid therapy: case report. The Journal of Clinical Endocrinology and Metabolism. 2001;86:675–678
  33. Nikfarjam L, Kominami S, Yamazaki T, et al. Mechanism of inhibition of cytochrome P450 C21 enzyme activity by autoantibodies from patients with Addison's disease. European Journal of Endocrinology. 2005;152:95–101
  34. Bøe AS, Bredholt G, Knappskog PM, et al. Autoantibodies against 21-hydroxylase and side-chain cleavage enzyme in autoimmune Addison's disease are mainly immunoglobulin G1. European Journal of Endocrinology. 2004;150:49–56
  35. Nikoshkov A, Falorni A, Lajic S, et al. A conformation-dependent epitope in Addison's disease and other endocrinological autoimmune diseases maps to a carboxyl-terminal functional domain of human steroid 21-hydroxylase. Journal of Immunology. 1999;162:2422–2426
  36. Volpato M, Prentice L, Chen S, et al. A study of the epitopes on steroid 21-hydroxylase recognized by autoantibodies in patients with or without Addison's disease. Clinical and Experimental Immunology. 1998;111:422–428
  37. Wedlock N, Asawa T, Baumann-Antczak A, et al. Autoimmune Addison's disease. Analysis of autoantibody binding sites on human steroid 21-hydroxylase. FEBS Letters. 1993;332:123–126
  38. Boscaro M, Betterle C, Volpato M, et al. Hormonal responses during various phases of autoimmune adrenal failure: no evidence for 21-hydroxylase enzyme activity inhibition in vivo. The Journal of Clinical Endocrinology and Metabolism. 1996;81:2801–2804
  39. Betterle C, Pra CD, Pedini B, et al. Assessment of adrenocortical function and autoantibodies in a baby born to a mother with autoimmune polyglandular syndrome Type 2. Journal of Endocrinological Investigation. 2004;27:618–621
  40. Yanaba K, Bouaziz JD, Matsushita T, et al. B-lymphocyte contributions to human autoimmune disease. Immunological Reviews. 2008;223:284–299
  41. Söderbergh A, Myhre AG, Ekwall O, et al. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. The Journal of Clinical Endocrinology and Metabolism. 2004;89:557–562
  42. Alimohammadi M, Björklund P, Hallgren A, et al. Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. The New England Journal of Medicine. 2008;358:1018–1028
  43. Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science. 2002;298:1395–1401
  44. Meager A, Visvalingam K, Peterson P, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Medicine. 2006;3:e289
  45. Meloni A, Furcas M, Cetani F, et al. Autoantibodies against type I Interferons as an additional diagnostic criteria for Autoimmune Polyendocrine Syndrome Type I. The Journal of Clinical Endocrinology and Metabolism. 2008;77:1753–1756
  46. al Sabri AM, Smith N, Busuttil A. Sudden death due to auto-immune Addison's disease in a 12-year-old girl. International Journal of Legal Medicine. 1997;110:278–280
  47. Hayashi Y, Hiyoshi T, Takemura T, et al. Focal lymphocytic infiltration in the adrenal cortex of the elderly: immunohistological analysis of infiltrating lymphocytes. Clinical and Experimental Immunology. 1989;77:101–105
  48. Nerup J, Andersen V, Bendixen G. Anti-adrenal, cellular hypersensitivity in Addison's disease. Clinical and Experimental Immunology. 1969;4:355–363
  49. Nerup J, Andersen V, Bendixen G. Anti-adrenal cellular hypersensitivity in Addison's disease. IV. In vivo and in vitro investigations on the mitochondrial fraction. Clinical and Experimental Immunology. 1970;6:733–739
  50. Kriegel MA, Lohmann T, Gabler C, et al. Defective suppressor function of human CD4 + CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. The Journal of Experimental Medicine. 2004;199:1285–1291
  51. Vendrame F, Segni M, Grassetti D, et al. Impaired caspase-3 expression by peripheral T cells in chronic autoimmune thyroiditis and in autoimmune polyendocrine syndrome-2. The Journal of Clinical Endocrinology and Metabolism. 2006;91:5064–5068
  52. Husebye ES, Bratland E, Bredholt G, et al. The substrate-binding domain of 21-hydroxylase, the main autoantigen in autoimmune Addison's disease, is an immunodominant T cell epitope. Endocrinology. 2006;147:2411–2416
  53. Robles DT, Fain PR, Gottlieb PA, et al. The genetics of autoimmune polyendocrine syndrome type II. Endocrinology and Metabolism Clinics of North America. 2002;31:353–368vi–vii
  54. Yu L, Brewer KW, Gates S, et al. DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease. The Journal of Clinical Endocrinology and Metabolism. 1999;84:328–335
  55. Gombos Z, Hermann R, Kiviniemi M, et al. Analysis of extended human leukocyte antigen haplotype association with Addison's disease in three populations. European Journal of Endocrinology. 2007;157:757–761
  56. Gambelunghe G, Kockum I, Bini V, et al. Retrovirus-like long-terminal repeat DQ-LTR13 and genetic susceptibility to type 1 diabetes and autoimmune Addison's disease. Diabetes. 2005;54:900–905
  57. Undlien DE, Friede T, Rammensee HG, et al. HLA-encoded genetic predisposition in IDDM: DR4 subtypes may be associated with different degrees of protection. Diabetes. 1997;46:143–149
  58. Nejentsev S, Howson JM, Walker NM, et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature. 2007;450:887–892
  59. Gambelunghe G, Falorni A, Ghaderi M, et al. Microsatellite polymorphism of the MHC class I chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune Addison's disease. The Journal of Clinical Endocrinology and Metabolism. 1999;84:3701–3707
  60. Park YS, Sanjeevi CB, Robles D, et al. Additional association of intra-MHC genes, MICA and D6S273, with Addison's disease. Tissue Antigens. 2002;60:155–163
  61. Field SF, Nejentsev S, Walker NM, et al. Sequencing-based genotyping and association analysis of the MICA and MICB genes in type 1 diabetes. Diabetes. 2008;
  62. Yanagawa T, Hidaka Y, Guimaraes V, et al. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. The Journal of Clinical Endocrinology and Metabolism. 1995;80:41–45
  63. Vaidya B, Pearce S. The emerging role of the CTLA-4 gene in autoimmune endocrinopathies. European Journal of Endocrinology. 2004;150:619–626
  64. Vaidya B, Imrie H, Geatch DR, et al. Association analysis of the cytotoxic T lymphocyte antigen-4 (CTLA-4) and autoimmune regulator-1 (AIRE-1) genes in sporadic autoimmune Addison's disease. The Journal of Clinical Endocrinology and Metabolism. 2000;85:688–691
  65. Kemp EH, Ajjan RA, Husebye ES, et al. A cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism is associated with autoimmune Addison's disease in English patients. Clinical Endocrinology. 1998;49:609–613
  66. Perez de Nanclares G, Martin-Pagola A, Ramon Bilbao J, et al. No evidence of association of CTLA4 polymorphisms with Addison's disease. Autoimmunity. 2004;37:453–456
  67. Donner H, Braun J, Seidl C, et al. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease. The Journal of Clinical Endocrinology and Metabolism. 1997;82:4130–4132
  68. Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003;423:506–511
  69. Blomhoff A, Lie BA, Kemp EH, et al. Polymorphisms in the CTLA4 gene region confer susceptibility to Addison's disease. The Journal of Clinical Endocrinology and Metabolism. 2004;89:3474–3476
  70. Chase K, Sargan D, Miller K, et al. Understanding the genetics of autoimmune disease: two loci that regulate late onset Addison's disease in Portuguese Water Dogs. International Journal of Immunogenetics. 2006;33:179–184
  71. Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nature Genetics. 2004;36:337–338
  72. Vang T, Miletic AV, Bottini N, et al. Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity. 2007;40:453–461
  73. Velaga MR, Wilson V, Jennings CE, et al. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. The Journal of Clinical Endocrinology and Metabolism. 2004;89:5862–5865
  74. Kahles H, Ramos-Lopez E, Lange B, et al. Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto's thyroiditis or Addison's disease in the German population. European Journal of Endocrinology. 2005;153:895–899
  75. Skinningsrud B, Husebye ES, Gervin K, et al. Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease. European Journal of Human Genetics. 2008;16:977–982
  76. Todd JA, Walker NM, Cooper JD, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nature Genetics. 2007;39:857–864
  77. Ghaderi M, Gambelunghe G, Tortoioli C, et al. MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency. The Journal of Clinical Endocrinology and Metabolism. 2006;91:4107–4111
  78. Dziembowska M, Fondaneche MC, Vedrenne J, et al. Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency. Immunogenetics. 2002;53:821–829
  79. Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of Type 1 Diabetes: a systematic review and meta-analysis. Archives of Disease in Childhood. 2008;93:512–517
  80. Mathieu C, Waer M, Laureys J, et al. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia. 1994;37:552–558
  81. Pani MA, Seissler J, Usadel KH, et al. Vitamin D receptor genotype is associated with Addison's disease. European Journal of Endocrinology. 2002;147:635–640
  82. Lopez ER, Zwermann O, Segni M, et al. A promoter polymorphism of the CYP27B1 gene is associated with Addison's disease, Hashimoto's thyroiditis, Graves' disease and type 1 diabetes mellitus in Germans. European Journal of Endocrinology. 2004;151:193–197
  83. Jennings CE, Owen CJ, Wilson V, et al. A haplotype of the CYP27B1 promoter is associated with autoimmune Addison's disease but not with Graves' disease in a UK population. Journal of Molecular Endocrinology. 2005;34:859–863
  84. Bailey R, Cooper JD, Zeitels L, et al. Association of the vitamin D metabolism gene CYP27B1 with type 1 diabetes. Diabetes. 2007;56:2616–2621
  85. Owen CJ, Eden JA, Jennings CE, et al. Genetic association studies of the FOXP3 gene in Graves' disease and autoimmune Addison's disease in the United Kingdom population. Journal of Molecular Endocrinology. 2006;37:97–104
  86. Bøe Wolff AS, Oftedal B, Johansson S, et al. AIRE variations in Addison's disease and autoimmune polyendocrine syndromes (APS): partial gene deletions contribute to APS I. Genes and Immunity. 2008;9:130–136
  87. Jin Y, Mailloux CM, Gowan K, et al. NALP1 in vitiligo-associated multiple autoimmune disease. The New England Journal of Medicine. 2007;356:1216–1225
  88. Jin Y, Birlea SA, Fain PR, et al. Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population. The Journal of Investigative Dermatology. 2007;127:2558–2562
  89. Lindblad-Toh K, Wade CM, Mikkelsen TS, et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature. 2005;438:803–819
  90. Karlsson EK, Baranowska I, Wade CM, et al. Efficient mapping of mendelian traits in dogs through genome-wide association. Nature Genetics. 2007;39:1321–1328
  91. Oberbauer AM, Bell JS, Belanger JM, et al. Genetic evaluation of Addison's disease in the Portuguese Water Dog. BMC Veterinary Research. 2006;2:15
  92. Kooistra HS, Rijnberk A, van den Ingh TS. Polyglandular deficiency syndrome in a boxer dog: thyroid hormone and glucocorticoid deficiency. The Veterinary Quarterly. 1995;17:59–63
  93. Myhre AG, Halonen M, Eskelin P, et al. Autoimmune polyendocrine syndrome type 1 (APS I) in Norway. Clinical Endocrinology. 2001;54:211–217
  94. Ahonen P, Myllarniemi S, Sipila I, et al. Clinical variation of autoimmune polyendocrinopathy-candidiasis- ectodermal dystrophy (APECED) in a series of 68 patients. The New England Journal of Medicine. 1990;322:1829–1836
  95. Nagamine K, Peterson P, Scott HS, et al. Positional cloning of the APECED gene. Nature Genetics. 1997;17:393–398
  96. Consortium TF-GA. Autoimmune polyendocrinopathy-Candidiasis-Ectodermal Dystrophy. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nature Genetics. 1997;17:399–403
  97. Liston A, Lesage S, Wilson J, et al. Aire regulates negative selection of organ-specific T cells. Nature Immunology. 2003;4:350–354
  98. Mathis D, Benoist C. A decade of AIRE. Nature Reviews. Immunology. 2007;7:645–650
  99. Gardner JM, Devoss JJ, Friedman RS, et al. Deletional tolerance mediated by extrathymic Aire-expressing cells. Science. 2008;321:843–847

PII: S1521-690X(08)00102-4

doi: 10.1016/j.beem.2008.09.004

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 2 , Pages 147-157 , April 2009

Article Tools